Is Johnson & Johnson Stock A Better Pick Over Its Peer?
We believe Johnson & Johnson stock (NYSE: JNJ) is currently a better pick than Eli Lilly stock (NYSE: LLY), given its better prospects. Although Eli Lilly If we look at stock returns, Eli Lilly, with a stellar 34% rise this year, has fared far better than J&J, up just 4%, and both have…#trulicity #usfda #tremfya #jjs #stelara #elililly #trefismachinelearning #jnj #elilillys #johnsonjohnson (Source: Reuters: Health)
Source: Reuters: Health - December 5, 2022 Category: Consumer Health News Source Type: news
Ustekinumab During Pregnancy in Patients With IBD Ustekinumab During Pregnancy in Patients With IBD
This study assesed both maternal and neonatal outcomes.Alimentary Pharmacology & Therapeutics (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - November 25, 2022 Category: Consumer Health News Tags: Gastroenterology Journal Article Source Type: news
New TREMFYA ® (guselkumab) Post-Hoc Analysis Reveals Early Efficacy Predicted Longer-Term Efficacy And Sustained Achievement Among A Diverse Active Psoriatic Arthritis Patient Population
SPRING HOUSE, PENNSYLVANIA, November 11, 2022 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced a new post-hoc analysis of the Phase 3 DISCOVER program (DISCOVER-1 and DISCOVER-2) evaluating TREMFYA® (guselkumab) in adult patients with active psoriatic arthritis (PsA), which showed that early skin and enthesitis responsesa,b predicted longer-term clinical response,c including disease remission, at week 52.1 TREMFYA is the first fully human selective interleukin (IL)-23 inhibitor therapy approved in the U.S. for adults with moderate to severe plaque psoriasis (PsO) and adults with active PsA...
Source: Johnson and Johnson - November 11, 2022 Category: Pharmaceuticals Tags: Latest News Source Type: news
Two More IBD Drugs Cleared for Safety During Pregnancy
(MedPage Today) -- In utero exposure to ustekinumab (Stelara) or vedolizumab (Entyvio) proved as safe as other treatments for inflammatory bowel disease (IBD) during pregnancy, according to an updated analysis from the PIANO registry.
Among over... (Source: MedPage Today Gastroenterology)
Source: MedPage Today Gastroenterology - October 26, 2022 Category: Gastroenterology Source Type: news
Two Biologics Equally Effective for EIM of IBD Two Biologics Equally Effective for EIM of IBD
Ustekinumab and vedolizumab have similar effects on extraintestinal manifestations of inflammatory bowel disease, a real-world, retrospective analysis finds.Medscape Medical News (Source: Medscape Rheumatology Headlines)
Source: Medscape Rheumatology Headlines - October 22, 2022 Category: Rheumatology Tags: Gastroenterology News Source Type: news
Johnson & Johnson Reports Q3 2022 Results
New Brunswick, N.J. (October 18, 2022) – Johnson & Johnson (NYSE: JNJ) today announced results for third-quarter 2022. “Our third quarter performance demonstrates our continued strength and resilience across all three of our businesses,” said Joaquin Duato, Chief Executive Officer. “Through the ongoing efforts of our teams around the world, we continue to navigate the dynamic macroeconomic environment and remain focused on delivering transformative healthcare solutions. Looking ahead, I remain confident in our business and ability to continue advancing our innovative portfolio and pipeline.”OVERALL FINANCIAL ...
Source: Johnson and Johnson - October 18, 2022 Category: Pharmaceuticals Tags: Financial Source Type: news
Biocon Biologics inks out-licensing agreement with Yoshindo Inc
Under the terms of this deal, Japan-based Yoshindo gets exclusive commercialisation rights in Japan for Ustekinumab and Denosumab -- developed and manufactured by Biocon Biologics -- for an addressable market opportunity of USD 700 million, Biocon Biologics said in a statement. (Source: The Economic Times Healthcare and Biotech News)
Source: The Economic Times Healthcare and Biotech News - October 17, 2022 Category: Pharmaceuticals Source Type: news
An Intestinal Transplant First; 4-Year Stelara Data in UC; Lymphoma After Anti-TNF
(MedPage Today) -- A 1-year-old girl from Spain is the world's first successful recipient of a multi-visceral intestinal transplant from a controlled donor in asystole. (Reuters)
Although probiotics containing the strain Bifidobacterium longum... (Source: MedPage Today Gastroenterology)
Source: MedPage Today Gastroenterology - October 13, 2022 Category: Gastroenterology Source Type: news
STELARA ® (ustekinumab) Demonstrated Sustained Symptomatic and Corticosteroid-Free Remission Through Four Years in Adults with Moderately to Severely Active Ulcerative Colitis
SPRING HOUSE, PENNSYLVANIA, October 10, 2022 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced final data from the long-term extension (LTE) of the Phase 3 UNIFI study demonstrating efficacy and safety of STELARA® (ustekinumab) through four years of treatment in adult patients with moderately to severely active ulcerative colitis (UC).1 Among all patients who had achieved clinical responsea with STELARA during induction, 64.9 percent were in symptomatic remissionb after 44 weeks of maintenance. At week 200 (four years), this proportion of patients was 55.2 percent; the majority (96.4 percen...
Source: Johnson and Johnson - October 10, 2022 Category: Pharmaceuticals Source Type: news
FDA Clears AI Polyp Detection Device; IBD and Sexual Issues; Stelara in Pregnancy
(MedPage Today) -- The FDA cleared the artificial intelligence-assisted Skout polyp detection device for adults undergoing colorectal cancer screening and surveillance, Iterative Scopes announced.
Nexpowder, an endoscopic hemostasis system that... (Source: MedPage Today Gastroenterology)
Source: MedPage Today Gastroenterology - September 29, 2022 Category: Gastroenterology Source Type: news
Noninvasive Gastric Mapping; Best Foods for the Gut? Lab Score for Crohn's
(MedPage Today) -- Could a novel noninvasive gastric mapping device that measures stomach activity offer new insights into chronic nausea and vomiting? (Science Translational Medicine)
Vedolizumab (Entyvio) and ustekinumab (Stelara) were both... (Source: MedPage Today Gastroenterology)
Source: MedPage Today Gastroenterology - September 22, 2022 Category: Gastroenterology Source Type: news
Ustekinumab Becomes Second Biologic Approved for PsA in Kids Ustekinumab Becomes Second Biologic Approved for PsA in Kids
The approval is based on an extrapolation of data from adult trials in active psoriatic arthritis and adult and pediatric studies in moderate to severe plaque psoriasis.FDA Approvals (Source: Medscape Dermatology Headlines)
Source: Medscape Dermatology Headlines - August 2, 2022 Category: Dermatology Tags: Rheumatology News Alert Source Type: news
Comorbidities Key to Serious Infections With IBD Treatment Comorbidities Key to Serious Infections With IBD Treatment
Older IBD patients with comorbidities are less likely to be hospitalized due to an infection if they are treated with vedolizumab or ustekinumab than with an anti-TNF agent, suggests a US study.Medscape Medical News (Source: Medscape Allergy Headlines)
Source: Medscape Allergy Headlines - August 1, 2022 Category: Allergy & Immunology Tags: Gastroenterology News Source Type: news
STELARA ® (ustekinumab) Approved by the U.S. Food and Drug Administration to Treat Pediatric Patients with Active Psoriatic Arthritis
HORSHAM, PENNSYLVANIA, August 1, 2022 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced that the U.S. Food and Drug Administration (FDA) has approved STELARA® (ustekinumab) for the treatment of pediatric patients six years of age and older with active psoriatic arthritis (PsA). This rare disease that resembles adult PsA affects five to eight percent of children and adolescents with chronic inflammatory arthritis.*1-7 Two of the four indications for STELARA now include pediatric patients, further expanding its treatment profile since the first approval in 2009 for adults living with moderate...
Source: Johnson and Johnson - August 1, 2022 Category: Pharmaceuticals Tags: Latest News Source Type: news
Stelara (ustekinumab) Approved by the U.S. Food and Drug Administration to Treat Pediatric Patients with Active Psoriatic Arthritis
As the first and only biologic targeting both cytokines interleukin (IL)-12 and IL-23, Stelara provides a new therapeutic option for children six years of age and older living with active psoriatic arthritis
Active psoriatic arthritis in... (Source: Drugs.com - New Drug Approvals)
Source: Drugs.com - New Drug Approvals - August 1, 2022 Category: Drugs & Pharmacology Source Type: news
